

COMPANY OVERVIEW

We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Our lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, the Company's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The Company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

RECENT NEWS

[Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update](#)

Nov 15 2017, 7:05 AM EST

[Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc](#)

Nov 2 2017, 8:05 AM EDT

STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	19.28m
Last Price	\$2.05
52-Week Range	\$1.3691 - \$8.95

01/23/2019 04:00 PM EST

INVESTOR RELATIONS

Jenene Thomas Communications, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com

MANAGEMENT TEAM

Jeffrey F. Eisenberg
Chief Executive Officer

Curtis Lockshin, Ph.D.
Chief Scientific Officer

James F. Parslow
Chief Financial Officer

XENETIC BIOSCIENCES, INC.

99 Hayden Avenue
Suite 230
Lexington, MA 02421
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.